NCT00800683 - Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive | Biotech Hunter

Enrollment

133

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

January 31, 2011

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

BI 1356

BI 1356 dosed once daily

DRUG

placebo

placebo matching BI 1356 taken once daily

Trial Locations (53)

Unknown

1218.43.10027 Boehringer Ingelheim Investigational Site, Phoenix

1218.43.10011 Boehringer Ingelheim Investigational Site, Chula Vista

1218.43.10006 Boehringer Ingelheim Investigational Site, Riverside

1218.43.10021 Boehringer Ingelheim Investigational Site, Whittier

1218.43.10013 Boehringer Ingelheim Investigational Site, Pembroke Pines

1218.43.10009 Boehringer Ingelheim Investigational Site, West Palm Beach

1218.43.10018 Boehringer Ingelheim Investigational Site, Decatur

1218.43.10022 Boehringer Ingelheim Investigational Site, Chicago

1218.43.10015 Boehringer Ingelheim Investigational Site, Shreveport

1218.43.10016 Boehringer Ingelheim Investigational Site, Kansas City

1218.43.10003 Boehringer Ingelheim Investigational Site, Great Neck

1218.43.10004 Boehringer Ingelheim Investigational Site, The Bronx

1218.43.10020 Boehringer Ingelheim Investigational Site, Winston-Salem

1218.43.10019 Boehringer Ingelheim Investigational Site, Delaware

1218.43.10008 Boehringer Ingelheim Investigational Site, Mentor

1218.43.10005 Boehringer Ingelheim Investigational Site, Bethlehem

1218.43.10007 Boehringer Ingelheim Investigational Site, Carlisle

1218.43.10001 Boehringer Ingelheim Investigational Site, Providence

1218.43.10025 Boehringer Ingelheim Investigational Site, Aiken

1218.43.10023 Boehringer Ingelheim Investigational Site, Austin

1218.43.10024 Boehringer Ingelheim Investigational Site, Austin

1218.43.10014 Boehringer Ingelheim Investigational Site, Dallas

1218.43.10017 Boehringer Ingelheim Investigational Site, Lufkin

1218.43.10010 Boehringer Ingelheim Investigational Site, Tacoma

1218.43.61009 Boehringer Ingelheim Investigational Site, Gosford

1218.43.61010 Boehringer Ingelheim Investigational Site, Auchenflower

1218.43.61006 Boehringer Ingelheim Investigational Site, Kippa-Ring

1218.43.61007 Boehringer Ingelheim Investigational Site, Reservoir

1218.43.61011 Boehringer Ingelheim Investigational Site, Richmond

1218.43.61005 Boehringer Ingelheim Investigational Site, Adelaide, SA

1218.43.61002 Boehringer Ingelheim Investigational Site, Herston, QLD

1218.43.85201 Boehringer Ingelheim Investigational Site, Hong Kong

1218.43.85203 Boehringer Ingelheim Investigational Site, New Territories

1218.43.97008 Boehringer Ingelheim Investigational Site, Afula

1218.43.97005 Boehringer Ingelheim Investigational Site, Ashkelon

1218.43.97003 Boehringer Ingelheim Investigational Site, Haifa

1218.43.97004 Boehringer Ingelheim Investigational Site, Jerusalem

1218.43.97009 Boehringer Ingelheim Investigational Site, Jerusalem

1218.43.97002 Boehringer Ingelheim Investigational Site, Kfar Saba

1218.43.97007 Boehringer Ingelheim Investigational Site, Nahariya

1218.43.97001 Boehringer Ingelheim Investigational Site, Safed

1218.43.97006 Boehringer Ingelheim Investigational Site, Tel Aviv

1218.43.64001 Boehringer Ingelheim Investigational Site, Auckland

1218.43.64003 Boehringer Ingelheim Investigational Site, Christchurch

1218.43.64004 Boehringer Ingelheim Investigational Site, Takpuna

1218.43.64002 Boehringer Ingelheim Investigational Site, Tauranga

1218.43.38003 Boehringer Ingelheim Investigational Site, Kharkiv

1218.43.38004 Boehringer Ingelheim Investigational Site, Kharkiv

1218.43.38006 Boehringer Ingelheim Investigational Site, Kharkiv

1218.43.38005 Boehringer Ingelheim Investigational Site, Kiev

1218.43.38007 Boehringer Ingelheim Investigational Site, Luhansk

1218.43.38008 Boehringer Ingelheim Investigational Site, Ternopil

1218.43.38002 Boehringer Ingelheim Investigational Site, Zaporizhzhya